on paper it looks like a smart move for clinical trials to be done where there is
a) an emerging financial market
b) access to greater clinical population
c) possibly less stringency and red tape.
I think with our financial position it makes sense to go this way. my worry is that the long term the data will not be as widely accepted as trials and data from more developed western countries would be. especially if the end game is FDA approval.
Ann: RCE Establishes Strategic Partnership in South-East Asia, page-5
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
-0.005(0.90%) |
Mkt cap ! $112.1M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 55.5¢ | 53.0¢ | $11.03K | 20.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 42 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.5¢ | 11882 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
54.5¢ |
Change
-0.005 ( 0.46 %) |
||||
| Open | High | Low | Volume | ||
| 54.5¢ | 54.5¢ | 54.5¢ | 5597 | ||
| Last updated 15.31pm 13/06/2024 ? | |||||
| RCE (ASX) Chart |